Allarity Therapeutics, Inc. 10-K Cybersecurity GRC - 2024-03-08

Page last updated on July 16, 2024

Allarity Therapeutics, Inc. reported their cybersecurity risk management and governance process in a yearly 10-K filed on 2024-03-08 07:15:55 EST.


10-K filed on 2024-03-08

Allarity Therapeutics, Inc. filed a 10-K at 2024-03-08 07:15:55 EST
Accession Number: 0001213900-24-020864

Note: filing items unformatted. Drop us a note with the above URL to help us prioritize formatting it!

Item 1C. Cybersecurity.

Item 1C. Cybersecurity. We continue to augment the capabilities of our people, processes, and technologies in order to address our cybersecurity risks. Our cybersecurity risks, and the controls designed to mitigate those risks, are integrated into our overall risk management governance and are reviewed yearly by our Board of Directors. Risk Management and Strategy As of December 31, 2023, we have implemented a set of cybersecurity and data protection policies and procedures. Risks from cybersecurity threats are regularly evaluated as a part of our broader risk management activities. Our employees have received cybersecurity awareness trainings, including specific topics related to social engineering and email frauds. Important security measures such as multifactor authentication, firewalls, Endpoint Detection and Response (EDR), encryption, etc. have been implemented. We continue to augment the capabilities of our people, processes, and technologies in order to address our cybersecurity risks. Currently we are in the process of expanding our risk management procedure to include a broader cybersecurity risk management process. The updated risk management process will include annual review by our Board of Directors Governance Our Board of Directors are currently implementing as oversight procedure for IT governance and cyber security risk management. It is expected that IT governance and cybersecurity will be included in the company’s quarterly management review meetings under the supervision of our senior leadership, including our Chief Executive Officer and Chief Financial Officer, with regularly meets with and provides periodic briefings to our Board of Directors regarding our cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like. Cybersecurity Threat Disclosure To date, we are not aware of any cybersecurity threats that have materially affected or are reasonably likely to materially affect the Company. For further discussion of cybersecurity risks, please see Item 1A, " Risk Factors ."

Company Information

NameAllarity Therapeutics, Inc.
SIC DescriptionPharmaceutical Preparations
TickerALLR - Nasdaq
Emerging growth company
Fiscal Year EndDecember 30